Canton Strategic Holdings (CNTN) Change in Accured Expenses (2021 - 2026)
Canton Strategic Holdings (CNTN) reported Change in Accured Expenses of -$1.5 million for Q1 2026, down 22752.21% on a YoY basis from N/an in Q1 2025, and down 196.73% quarter-over-quarter from $1.5 million in Q4 2025.
Canton Strategic Holdings (CNTN) Change in Accured Expenses (2021 - 2026) Analysis & Trends
Canton Strategic Holdings has reported Change in Accured Expenses for 6 years, with the latest figure at -$1.5 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses fell 22752.21% year-over-year to -$1.5 million; the trailing twelve-month figure through Mar 2026 stood at -$378695.0 (down 147.91% YoY), and the FY2025 full-year result was $1.1 million, up 156.55% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$1.5 million, down from $1.5 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $1.5 million in Q4 2025, with the low at -$1.5 million in Q1 2026.
- Historically, Change in Accured Expenses has averaged $36530.7 across 5 years, with a median of -$6376.0 in 2025.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses soared 6658.29% — and 2026, when it tumbled 22752.21%.
- Canton Strategic Holdings' Change in Accured Expenses stood at $10597.0 in 2022, then soared by 6658.29% to $716176.0 in 2023, then plunged by 106.25% to -$44774.0 in 2024, then surged by 3464.2% to $1.5 million in 2025, then plunged by 196.73% to -$1.5 million in 2026.
- The last three Change in Accured Expenses figures came in at -$1.5 million (Q1 2026), $1.5 million (Q4 2025), and -$368137.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 931,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Canton Strategic Holdings | 699.97 Mn | 658.44 Mn | - | -1.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.46 Mn |
| Mar 31, 2026 | -1.46 Mn |
| Dec 31, 2025 | 1.51 Mn |
| Dec 31, 2025 | 1.51 Mn |
| Sep 30, 2025 | -368,137.00 |
| Sep 30, 2025 | -368,137.00 |
| Jun 30, 2025 | -59,787.00 |
| Jun 30, 2025 | -59,787.00 |
| Mar 31, 2025 | -6,376.00 |
| Mar 31, 2025 | -6,376.00 |
| Dec 31, 2024 | -44,774.00 |
| Dec 31, 2024 | -44,774.00 |
| Sep 30, 2024 | 789,628.00 |
| Sep 30, 2024 | 789,628.00 |
| Jun 30, 2024 | 51,935.00 |
| Jun 30, 2024 | 51,935.00 |
| Mar 31, 2024 | -378,942.00 |
| Mar 31, 2024 | -378,942.00 |
| Dec 31, 2023 | 716,176.00 |
| Dec 31, 2023 | 716,176.00 |